Benzinga's Top Pre-Market Losers

ArQule

dipped 61.92% to $1.90 in the pre-market session. ArQule and Daiichi Sankyo Co reported discontinuation of Phase 3 MARQUEE trial in non-small cell lung cancer. Express

shares dropped 18.05% to $12.30 in pre-market trading. Express issued downbeat Q3 profit forecast. Fifth & Pacific Companies

dipped 14.25% to $10.95 in the pre-market session. Fifth & Pacific Companies

lowered its 2012 outlook. Novavax

shares fell 7.11% to $2.22 in the pre-market trading. Novavax's trailing-twelve-month operating margin is -95.36%.